| |
| |
|
|
 |
| |
 |
 |
 |
|
|
| |
 |
|
| |
Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of
novel cancer therapeutics. We are in the business of solving problems for patients with cancer. We
have multiple products in the clinical stage of development, including eniluracil, ADH-1 and sodium
thiosulfate (STS).
Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, is being developed to improve the
tolerability and effectiveness of 5-fluorouracil (5-FU), one of the most widely used oncology drugs in
the world. ADH-1 is a biotechnology compound which selectively targets N-cadherin, a protein present on
certain tumor cells and the blood vessels of solid tumors. STS is a chemoprotectant being developed to
reduce or prevent hearing loss that may result from treatment with platinum-based chemotherapy drugs.
With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management
team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex aims
to become a leader in developing innovative treatments that address important unmet medical needs in cancer.
Website: www.adherex.com
|
|
|
| |
|
|
|
